{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:30:07Z","timestamp":1748964607142},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T00:00:00Z","timestamp":1435622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to establish the risk of liver toxicity in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\/hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>)\u2010coinfected patients receiving etravirine, according to the degree of liver fibrosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective cohort study of 211 <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected patients initiating an etravirine\u2010containing regimen was carried out. <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> coinfection was defined as a positive <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> test, and baseline liver fibrosis was assessed by transient elastography. Hepatotoxicity was defined as clinical symptoms, or an aspartate aminotransferase (<jats:styled-content style=\"fixed-case\">AST<\/jats:styled-content>) or alanine aminotransferase (<jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content>) value\u2009&gt;\u20095\u2010fold higher than the upper limit of normal if baseline values were normal, or 3.5\u2010fold higher if values were altered at baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 145 patients (69%) were <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> coinfected, with a lower nadir (165 versus 220 cells\/\u03bcL, respectively; p\u2009=\u20090.03) and baseline (374 versus 498 cells\/\u03bcL, respectively; p\u2009=\u20090.04) <jats:styled-content style=\"fixed-case\">CD4<\/jats:styled-content> count than monoinfected patients. Etravirine was mainly used with two nucleoside reverse transcriptase inhibitors (129; 61%) or with a boosted protease inhibitor (<jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>) (28%), with no significant differences according to <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> serostatus. Transient elastography in 117 patients (81%) showed a median (range) stiffness value of 8.25 (3.5\u201369) kPa, with fibrosis stage 1 in 43 patients (37%) and fibrosis stage 4 in 28 patients (24%). During an accumulated follow\u2010up time of 449.3 patient\u2010years (median 548 days), only one patient with advanced fibrosis (50.8\u2009kPa) had grade 3\u20134 liver toxicity (0.7%). Transaminases changed slightly, with no significant differences compared with baseline fibrosis, and nine and six patients had grade 1 and 2 transaminase increases, respectively. Also, <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> coinfection was not associated with a higher risk of discontinuation (25% discontinued versus 21% of monoinfected patients; p\u2009=\u20090.39, log\u2010rank test) or virological failure (8% versus 12%, respectively; p\u2009=\u20090.4).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data suggest that etravirine is a safe option for <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u2010coinfected patients, including those with significant liver fibrosis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12274","type":"journal-article","created":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T08:00:05Z","timestamp":1435651205000},"page":"62-67","source":"Crossref","is-referenced-by-count":9,"title":["Liver toxicity and risk of discontinuation in <scp>HIV<\/scp>\/hepatitis <scp>C<\/scp> virus\u2010coinfected patients receiving an etravirine\u2010containing antiretroviral regimen: influence of liver fibrosis"],"prefix":"10.1111","volume":"17","author":[{"given":"JL","family":"Casado","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases Ramon y Cajal Hospital  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mena","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine INIBIC\u2010Complexo Universitario Hospitalario  A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ba\u00f1\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Ramon y Cajal Hospital  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Castro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine INIBIC\u2010Complexo Universitario Hospitalario  A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Quereda","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Ramon y Cajal Hospital  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Ramon y Cajal Hospital  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Pedreira","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine INIBIC\u2010Complexo Universitario Hospitalario  A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Ramon y Cajal Hospital  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834c4c06"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1662"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.11.027"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl524"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/427216"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000425"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000069"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/520092"},{"key":"e_1_2_7_10_1","unstructured":"Division of AIDS (DAIDS).Table for grading the severity of adult and pediatric adverse events.2004. (Clarification August 2009). Available at:http:\/\/www.niaid.nih.gov(accessed 30 July 2014)."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01180.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01087.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp446"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1302-83"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1302-61"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq332"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097262"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181b4af1f"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.02.013"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.181"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.044404"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.07.008"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12274","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T10:59:28Z","timestamp":1696330768000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,30]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1111\/hiv.12274"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12274","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,30]]}}}